During the last decade, non-vitamin K antagonist oral anticoagulants (NOACs) revolutionized the thromboprophylaxis management of several medical conditions, including atrial fibrillation and venous thromboembolism. Dabigatran etexilate was the first NOAC widely available worldwide, and it is currently the only one that directly inhibits thrombin. More recently, the availability of idarucizumab, a specific reversal agent, has increased the safety of dabigatran use in clinical practice, especially for those patients with severe and life-threatening bleeding. This review aims to summarize current evidence on dabigatran, starting from its pharmacological characteristics, and providing an updated overview of pivotal randomized controlled trials and real-world data on its efficacy and safety.
A comprehensive appraisal of dabigatran etexilate clinical evidence and applications : a 10-year-long story / G.F. Romiti, B. Corica, M. Proietti. - In: FUTURE CARDIOLOGY. - ISSN 1479-6678. - 17:2(2021), pp. 215-226. [10.2217/fca-2020-0084]
A comprehensive appraisal of dabigatran etexilate clinical evidence and applications : a 10-year-long story
M. Proietti
2021
Abstract
During the last decade, non-vitamin K antagonist oral anticoagulants (NOACs) revolutionized the thromboprophylaxis management of several medical conditions, including atrial fibrillation and venous thromboembolism. Dabigatran etexilate was the first NOAC widely available worldwide, and it is currently the only one that directly inhibits thrombin. More recently, the availability of idarucizumab, a specific reversal agent, has increased the safety of dabigatran use in clinical practice, especially for those patients with severe and life-threatening bleeding. This review aims to summarize current evidence on dabigatran, starting from its pharmacological characteristics, and providing an updated overview of pivotal randomized controlled trials and real-world data on its efficacy and safety.File | Dimensione | Formato | |
---|---|---|---|
romiti2020.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.39 MB
Formato
Adobe PDF
|
1.39 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.